CA-PSMF
Patient Safety Movement Foundation (PSMF) – a global non-profit dedicated to unifying those involved in the healthcare ecosystem, identifying challenges that are causing patient deaths, and creating actionable solutions to mitigate them – is pleased to announce the appointment of its new chairman of the board of directors – Michael A.E. Ramsay, MD, FRCA. It also reaffirms its commitment to patient health and safety with updates to its mission, vision and values; and reestablishes its goal of achieving ZERO preventable patient deaths by 2030.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200310005733/en/
As one of PSMF’s longest-standing board members, serving since 2013, Dr. Ramsay has been an advocate for patient safety in the anesthesia world since the 1980’s and embodies the values and principles set forth by the foundation. He is a renowned medical professional and the current president of the Baylor Scott & White Research Institute, where he spearheads clinically relevant research efforts. Well-known for the development and implementation of the Ramsay Sedation Scale – a tool that has been adopted globally, designed for interpreting the depth of sedation for patients in the critical care unit; he also serves as chairman of the Department of Anesthesiology and Pain Management at Baylor University Medical Center in Dallas, Texas.
“The Patient Safety Movement has achieved tremendous momentum in the eight years since its inception,” said Joe Kiani, founder and prior chairman of the board of the Patient Safety Movement Foundation. “Kindling this important movement has been an enormous part of my life’s work, and I am thrilled to pass the torch to Dr. Ramsay to carry our shared vision forward into the future with passion and enthusiasm.”
To date, the foundation has accomplished:
- Saving 366,353 lives since 2013
- Securing 48 countries with committed hospitals
- Securing 54 countries with partner groups (i.e. hospitals, open data pledge, other partners)
- Securing 4,793 total committed hospitals
- Securing 92 total pledges
- Securing 94 total partners
- Saving a total of 93,276 lives in 2019 alone
While the foundation did not achieve its prior goal of hitting zero preventable patient deaths by 2020, it renews the pledge with a new target goal of 2030.
“It is a great honor to be appointed chairman of the board of directors of the Patient Safety Movement Foundation,” states Dr. Ramsay. “Lives are being saved and patient harm is being prevented. We share monumentally important goals and have taken great leaps forward thus far; and I truly look forward to building upon the successes to date to achieve ZERO preventable patient deaths by 2030.” Dr. Ramsay has written his first “Letter from the Chairman” which is published monthly on the PSMF’s website. To read his first letter, visit: https://patientsafetymovement.org/newsletters/march-2020-issue-ii/letter-from-the-chairman-march-2020 .
The Patient Safety Movement Foundation will continue to provide tools, resources and guidelines aimed at educating healthcare providers, industry professionals, patients and families, to achieve its vision of a future that diminishes and ultimately eliminates preventable patient deaths. It will do so by:
- Prioritizing safety with patients at the center.
- Promoting dignity, compassion and respect in healthcare.
- Aligning everyone who influences or is touched by healthcare.
- Promoting transparency.
- Realigning incentives to achieve safer care.
- Informing caregivers, patients and families about patient safety.
- Identifying the preventable causes of patient harm and death, and then create and freely share actionable solutions (Actionable Patient Safety Solutions) to mitigate them.
- Driving the implementation of Actionable Patient Safety Solutions (APSS).
-
Asking healthcare technology companies to share data to create a Patient Data Superhighway.
To learn more about Patient Safety Movement Foundation, visit https://patientsafetymovement.org/ .
ABOUT PATIENT SAFETY MOVEMENT FOUNDATION: More than 200,000 people die every year in U.S. hospitals and 4.8 million worldwide in ways that could have been prevented. The Patient Safety Movement Foundation (PSMF) is a global non-profit working toward a future that diminishes and ultimately eliminates preventable patient deaths by offering tools, resources and guidelines aimed at educating healthcare providers, industry professionals, patients and families. It was established through the support of the Masimo Foundation for Ethics, Innovation and Competition in Healthcare to achieve the goal of ZERO preventable patient deaths. Achieving this goal requires a collaborative effort from all stakeholders, including patients, healthcare providers, medical technology companies, government, employers and private payers. The Patient Safety Movement Foundation is dedicated to unifying those involved in the healthcare ecosystem, identifying challenges that are causing patient deaths, creating actionable solutions to mitigate them, and partnering with hospitals who are committed to implementing its specific, high-impact solutions to meet patient safety challenges called Actionable Patient Safety Solutions (APSS) . The organization also encourages medical technology companies to share the data their products are purchased for, and asks hospitals to make commitments to implement Actionable Patient Safety Solutions. To learn more, visit patientsafetymovement.org.
Editor’s Note: To schedule interviews with the experts from Patient Safety Movement Foundation, please email jennifer@beyondfifteen.com or call 949.733.8679.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200310005733/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Australian Defence Force Secures Satellite Communications on SES IS-2212.1.2026 22:30:00 CET | Press release
New agreement for uninterrupted UHF connectivity for Australian Defence Force through 2033, With Options Extending to 2041 Satellite communications solutions provider SES will provide secure uninterrupted satellite communications to the Australian Defence Force (ADF) for a minimum of 16 years thanks to a new extended agreement. The service will be provided via the SES Intelsat 22 satellite and an ultra-high frequency (UHF) military communications payload. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112137182/en/ Assistant Secretary Space Systems Branch, Michael Hunt, formalizes contract negotiations for the through-life support of the IS-22 satellite with Rory Welch, senior vice-president of service delivery at SES Space and Defense. Photos: Corporal Annika Smit Under the renewed arrangement, SES will reposition the IS-22 satellite to a new orbital slot specified by the ADF, continuing a mission that has been the corne
NetApp Appoints Paul Fipps to the Board of Directors12.1.2026 22:05:00 CET | Press release
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that Paul Fipps, President of Global Customer Operations at ServiceNow, has joined its Board of Directors. The board now has ten directors, nine of whom are independent, and 50% of whom have been appointed within the last five years. Fipps brings more than 20 years of experience driving technology-enabled growth and customer transformation. At ServiceNow, he currently leads global sales, customer success, partner ecosystems, and field operations. He previously served as EVP of Worldwide Sales at ServiceNow and as President of Under Armour Connected Fitness and Chief Experience Officer at Under Armour, overseeing global direct-to-consumer, connected fitness, and digital experiences. He also previously served on the advisory board of Quantum Metric. Fipps holds a B.S. in Information Systems, an MBA from the University of Baltimore, and is a graduate of The Wharton School’s Advanced Management Program. “P
FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor12.1.2026 20:00:00 CET | Press release
Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s new drug application (NDA) for pimicotinib as a systemic treatment for patients with tenosynovial giant cell tumor (TGCT). The application is based on the primary results and longer-term follow-up of the global Phase 3 MANEUVER study, which demonstrated deep and durable tumor responses and meaningful improvements in clinical outcomes with pimicotinib. “With pimicotinib, we have an opportunity to significantly advance care for people living with TGCT, a painful and debilitating disease that has few effective and well-tolerated treatment options beyond surgery,” said David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “Based on clinical trial results showing not only a reduction in tumor burden, but also the ability to help alleviate symptoms like pain an
Fabentech receives Marketing Authorization for Ricimed®, an antidote against ricin poisoning12.1.2026 19:32:00 CET | Press release
First Marketing Authorization granted in France for the treatment of ricin poisoning, one of the most toxic natural substances in the world and a recognized priority biological threat. Ricimed® addresses a previously unmet medical need in the management of severe and potentially fatal ricin intoxications.Supported by the French Ministry of the Armed Forces and Veterans Affairs (the Directorate General of Armaments and the French Military Health Service), the development of Ricimed® illustrates Fabentech’s transition to a new scale and, with recent support from the European HERA Invest program, reinforces its positioning as a reference player in medical countermeasures against biological threats, serving both civilian and military markets. Fabentech, a French biopharmaceutical company specializing in medical countermeasures against biological threats, today announces that it has been granted Marketing Authorization for Ricimed®, a treatment for ricin poisoning. This press release featur
Traxys Group and the Shareholders of Comax2 AB - the holding company of Carbomax AB - sign Share Purchase Agreement to sell 100% interests to Traxys Group12.1.2026 19:20:00 CET | Press release
Traxys S.à.r.l., Investment Aktiebolaget Spiltan and other major shareholders of Comax 2 AB – the holding company of Carbomax AB –are pleased to announce that they have signed a Share Purchase Agreement (SPA) to sell 100% interests to Traxys Group. Carbomax AB is a leading Swedish trading house and industrial operator specializing in ferroalloys, carbon products and briquettes. The transaction aims to strengthen Traxys’ presence in the Scandinavian market and support the region’s transition toward sustainable steel production. Closing of the transaction is expected to occur in the first quarter 2026 following clearance by Swedish authorities, including foreign direct investment and antitrust approvals. Carbomax serves regional steel plants and most of foundries across the Nordics. With its strategic location near Västerås harbor and integrated processing capabilities Carbomax is well-positioned to capitalize on growing demand for green steel and sustainable raw materials. Mark Kristoff
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
